Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of BAM15 and Roxadustat — mechanism, side effects, legal status, and pricing.
BAM15 is a synthetic small-molecule mitochondrial uncoupler (protonophore) — not a peptide — studied preclinically for obesity and metabolic disease as a potentially safer alternative to DNP. It has never been tested in humans, has no regulatory approval, and was added to the WADA Prohibited List as an AMPK activator. It is sold as a gray-market research chemical.
Roxadustat (Evrenzo) is a small-molecule HIF-prolyl-hydroxylase inhibitor — not a peptide — that raises endogenous erythropoietin. It is an approved prescription drug for anemia of chronic kidney disease in China, Japan, and the EU, but the US FDA rejected it over safety signals. Because it boosts EPO/hemoglobin, it is diverted to the gray market for endurance doping and is WADA-prohibited at all times.
BAM15
Roxadustat
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
BAM15
Roxadustat
No pricing data yet.
Check Roxadustat prices →COA corpus from Disclosed Labs — independently tested batches only.
BAM15
3
COAs
99.1%
Avg purity
1
Labs
Roxadustat
3
COAs
99.8%
Avg purity
2
Labs
In diet-induced obese mice, BAM15 reduced fat mass and improved insulin sensitivity without changing food intake or lean mass (Nature Communications 2020); other mouse work shows benefit in diabetes, and in sepsis/acute kidney injury. Rodent PK is ~67% oral bioavailability with a ~1.7 h half-life; there is no human PK, safety, or dosing data. Not approved; not a peptide.
Key references
Roxadustat is supported by extensive human data as an approved anemia drug (China 2018, Japan 2019–2020, EU 2021 as Evrenzo) with numerous Phase 2/3 CKD trials. The US FDA advisory committee voted against approval in July 2021, citing thrombosis, seizures, infections, and mortality signals. No validated recreational or performance dose exists. Not FDA-approved; not a peptide.
BAM15 and Roxadustat are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs